Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers
- 27 October 2011
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 340 (2), 286-294
- https://doi.org/10.1124/jpet.111.188425
Abstract
The mechanism of action of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) involves the carrier-mediated and potentially vesicular release of monoamines. We assessed the effects of the sympatholytic α2-adrenergic receptor agonist clonidine (150 μg p.o.), which inhibits the neuronal vesicular release of norepinephrine, on the cardiovascular and psychotropic response to MDMA (125 mg p.o.) in 16 healthy subjects. The study used a randomized, double-blind, placebo-controlled crossover design with four experimental sessions. The administration of clonidine 1 h before MDMA reduced the MDMA-induced increases in plasma norepinephrine concentrations and blood pressure but only to the extent that clonidine lowered norepinephrine levels and blood pressure compared with placebo. Thus, no interaction was found between the cardiovascular effects of the two drugs. Clonidine did not affect the psychotropic effects or pharmacokinetics of MDMA. The lack of an interaction of the effects of clonidine and MDMA indicates that vesicular release of norepinephrine, which is inhibited by clonidine, does not critically contribute to the effects of MDMA in humans. Although clonidine may be used in the treatment of stimulant-induced hypertensive reactions, the present findings do not support a role for α2-adrenergic receptor agonists in the prevention of psychostimulant dependence.Keywords
This publication has 42 references indexed in Scilit:
- Cannabis Coadministration Potentiates the Effects of “Ecstasy” on Heart Rate and Temperature in HumansClinical Pharmacology & Therapeutics, 2009
- Effects on spontaneous and cocaine-induced behavior of pharmacological inhibition of noradrenergic and serotonergic systemsPharmacology Biochemistry and Behavior, 2008
- Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and PharmacokineticsJournal of Pharmacology and Experimental Therapeutics, 2007
- A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteersJournal of Psychopharmacology, 2006
- Role of α2A‐adrenoceptors in the effects of MDMA on body temperature in the mouseBritish Journal of Pharmacology, 2005
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in HumansPharmacopsychiatry, 1998
- Neuropharmacologic and Behavioral Actions of Clonidine: Interactions With Central NeurotransmittersInternational Review of Neurobiology, 1992
- Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sitesEuropean Journal of Pharmacology, 1988
- Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjectsEuropean Journal of Clinical Pharmacology, 1982
- The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report ScaleThe British Journal of Psychiatry, 1976